BetaGlue Therapeutics and its shareholders are proud to collaborate with Fondazione Policlinico Universitario Agostino Gemelli in the fight against cancer. Our clinical study in locally advanced pancreatic cancer is on-going. Learn more with this video.
EANM Annual Congress
October 17-21, 2026 | Austria Center Vienna
Vienna, Austria
Register interest: info@betaglue.com
ESMO Congress
October 25-27, 2026 | IFEMA Madrid
Madrid, Spain
Register interest: info@betaglue.com
LSI Europe Summit
September 28 – October 2, 2026 | Grand Hyatt Barcelona
Barcelona, Spain
Register interest: info@betaglue.com
CIRSE Annual Congress
September 5-9, 2026 | Bella Center Copenhagen
Copenhagen, Denmark
Register interest: info@betaglue.com
European Society for Medical Oncology
July 1-4, 2026 | ICM
Munich, Germany
Register interest: info@betaglue.com
American Society of Clinical Oncology
May 29-June 2, 2026 | McCormick Place
Chicago (IL), USA & Online
Register interest: info@betaglue.com
Annual Scientific Meeting
11-15 April, 2026 | Metro Toronto Convention Centre
Toronto (ON), Canada
Register interest: info@betaglue.com
LSI USA Summit
March 16-20, 2026 | Monarch Beach
Dana Point (CA), USA
Register interest: info@betaglue.com
World Congress of Interventional Oncology
January 26-27, 2026 | Università Cattolica del Sacro Cuore
Rome, Italy
Register interest: info@betaglue.com
Advancements in the fight against cancer
January 15-17, 2026 | JW Marriott Miami
Miami (FL), USA
Register interest: info@betaglue.com
44th Annual J.P. Morgan
January 12-15, 2026 | Westin St. Francis
San Francisco (CA), USA
Register interest: info@betaglue.com
Milan, May 27th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®,…
Read moreMilan, February 20th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called YntraDose®,…
Read moreMilan, December 16th 2024 - BetaGlue® Therapeutics S.p.A. (“BetaGlue”) an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumors, called…
Read more
